Survival Endpoints, Rigorous Phase IIs May Boost Cancer Vaccines’ Success
Executive Summary
SAN FRANCISCO - Stronger endpoints for survival and more rigorously designed Phase II trials are what will push the development of therapeutic cancer vaccines closer to the finish line, an industry panel said at a recent meeting at the Biotechnology Industry Organization Investor Forum
You may also be interested in...
Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials.
Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials.
Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials